The study includes two groups of patients: those who test positive for a specific hepatitis B marker called HBeAg and those who test negative for it. Some participants will receive ALG-000184, while others will receive Tenofovir Disoproxil or placebo. The treatment period lasts for 48 weeks, during which researchers will monitor how well the medications control the amount of hepatitis B virus in the blood.

Throughout the study, participants will have regular check-ups to monitor their health. These check-ups include blood tests to measure virus levels, liver function tests, physical examinations, and heart monitoring with ECGs. The total study duration may extend up to 96 weeks to ensure proper evaluation of the treatment’s long-term effects and safety.

The purpose of the study is to evaluate the effectiveness and safety of Bepirovirsen in achieving a functional cure for individuals with chronic hepatitis B who are already being treated with nucleos(t)ide analogues, a type of medication that helps control the virus. The study will last for 24 weeks, during which participants will receive Bepirovirsen with initial higher doses to help achieve the desired treatment effect. The goal is to see if Bepirovirsen can help reduce the virus to very low levels or eliminate it altogether, allowing participants to stop their current hepatitis B treatment.

Throughout the study, participants will be closely monitored to ensure their safety and to assess how well the treatment is working. The study aims to provide valuable information on whether Bepirovirsen can be an effective treatment option for people with chronic hepatitis B, potentially leading to a new way to manage this condition.

The purpose of this study is to assess the safety and tolerability of single and multiple doses of the study drug. During the course of the research, participants will receive the treatment to observe how the body processes the substances and how it affects various markers of the virus. Researchers will monitor levels of HBsAg, which is a protein on the surface of the virus, and HBV DNA, which is the genetic material of the virus, to see if the treatment helps reduce the presence of the infection.

The purpose of this study is to check the safety and effects of GSK3965193 when used alone and when combined with bepirovirsen in people living with chronic hepatitis B infection. The study will look at how well these medications are tolerated, how they work in the body, and whether they can reduce the amount of hepatitis B virus and virus-related proteins in the blood. The study is divided into four parts, with some parts testing the medication alone and other parts testing the combination of both medications.

During the study, participants will receive treatment for several weeks and will be monitored both during treatment and after treatment ends. The study will measure various markers of hepatitis B infection in the blood, including the amount of virus and specific proteins produced by the virus. Safety will be checked through regular blood tests, physical examinations, and monitoring for any unwanted effects. The total length of follow-up will vary depending on which part of the study participants join, with some participants being followed for several months after treatment to see the longer-term effects of the medications.

The purpose of the study is to understand how stopping these medications affects the virus in people who have been on treatment for a long time. The study will look at how the virus behaves after the treatment is stopped, particularly in people who are HBeAg negative, which means they do not have a specific protein in their blood that is often present in active hepatitis B infections. Participants will be monitored for changes in their health and the virus over a period of time after they stop taking the medication.

During the study, participants will take either the medication or a placebo, and their health will be closely monitored. The study will last for several months, and researchers will check the levels of the virus in the blood and other health markers to see how the virus responds to the treatment being stopped. The goal is to see if the virus remains under control without the medication and to understand the role of ethnicity in these outcomes. This information could help improve future treatment plans for people with chronic hepatitis B.

Participants in the study will receive either Terbinafine or a placebo, which looks like the medication but does not contain the active ingredient. The study will also examine the effects of Terbinafine when used alone or in combination with another medication called Tenofovir, which is already used to treat hepatitis B. The trial will last for a period of 10 weeks, during which participants will take the medication orally in the form of tablets.

The main goal of the study is to see if Terbinafine can reduce the levels of the virus in the blood and to monitor any side effects that may occur. By the end of the study, researchers hope to gather enough information to determine if Terbinafine is a safe and effective treatment option for people with chronic hepatitis B.

The purpose of this study is to evaluate how well these treatments work and how safe they are for people with chronic hepatitis B. Participants in the study will receive one or more of these treatments, or a placebo, over a period of up to 48 weeks. The study will monitor participants for any side effects and measure the effectiveness of the treatments in reducing the presence of the virus in the body. The study aims to find out if these treatments can help achieve a functional cure, which means the virus is no longer detectable in the blood and the liver functions normally.

Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. The study will also look at how the treatments affect specific markers of the virus in the blood, such as the levels of hepatitis B surface antigen (HBsAg) and hepatitis B virus DNA. The ultimate goal is to find a treatment regimen that is both safe and effective in managing or potentially curing chronic hepatitis B infection.

The medication is given as film-coated tablets in various strengths (245 mg, 204 mg, 163 mg, 123 mg) or as granules (33 mg/g), taken by mouth. The treatment period lasts for 192 weeks, which is approximately 3.7 years. During this time, doctors will monitor the amount of virus in the blood and check how well the liver is functioning through blood tests.

The study measures several important outcomes, including how many children achieve very low levels of the hepatitis B virus in their blood, improvements in liver function, and changes in certain proteins in the blood that indicate how the body is responding to the infection. The study also monitors the safety of the medication by checking bone density and other health indicators throughout the treatment period.

The purpose of the study is to evaluate the effectiveness and safety of Bepirovirsen in achieving a functional cure for individuals with chronic hepatitis B who are already being treated with nucleos(t)ide analogues, a type of medication that helps control the virus. The study will last for 24 weeks, during which participants will receive Bepirovirsen with initial higher doses to help achieve the desired treatment effect.

Throughout the study, participants will be monitored to assess the impact of the treatment on their condition. The goal is to determine if Bepirovirsen can help achieve a functional cure, meaning the virus is controlled without the need for ongoing medication. This study is part of a larger effort to find effective treatments for chronic hepatitis B and improve the quality of life for those affected by this condition.

The purpose of the study is to understand the durability of the treatment response. Participants in this study will have their health monitored over a period of time to see how their condition progresses after receiving bepirovirsen. The study will involve regular check-ups to assess the levels of certain markers in the blood that indicate the presence of the hepatitis B virus and the body’s response to the treatment. These markers include HBsAg, which is a protein on the surface of the hepatitis B virus, and HBV DNA, which is the genetic material of the virus.

Throughout the study, researchers will also look for any signs of the virus returning or any need for additional medication. The study aims to provide valuable information on how effective bepirovirsen is in maintaining a long-term response in people with chronic hepatitis B, helping to improve future treatment strategies for this condition.

The purpose of the study is to evaluate the safety and effectiveness of this sequential treatment in patients with Chronic Hepatitis B who are stable on their current therapy. Participants will be randomly assigned to receive either the new treatment or a placebo. The study will monitor how well the treatment works in reducing the virus and improving the immune response, as well as any side effects that may occur. The treatment will be administered through injections, with GSK3228836 given subcutaneously (under the skin) and GSK3528869A given intramuscularly (into the muscle).

Throughout the study, participants will have regular check-ups to assess their health and the treatment’s impact on the virus. The study aims to provide valuable information on whether this new treatment approach can offer a better way to manage Chronic Hepatitis B and improve patient outcomes. The trial is expected to continue until early 2026, allowing researchers to gather comprehensive data on the treatment’s long-term effects.

The purpose of the study is to assess the safety and how well people can tolerate the new vaccine treatment. Participants will receive the vaccine injections and will be monitored for any side effects or reactions. The study will also look at how the vaccine affects the liver and whether it helps reduce the amount of virus in the body. The trial will take place over a period of time, with participants receiving several injections and attending follow-up visits to check on their health and the vaccine’s effects.

Throughout the study, researchers will collect information on any side effects experienced by participants, as well as any changes in their health. The goal is to determine if the vaccine is safe and effective for people with chronic hepatitis B. This research could lead to new treatment options for those living with this condition.

The purpose of the study is to assess the safety and effectiveness of the RBD1016 Injection when used alongside existing treatments. Participants in the study will be randomly assigned to receive either the RBD1016 Injection or a placebo, which looks like the treatment but does not contain the active substance. The study will be conducted in a way that neither the participants nor the researchers know who is receiving the actual treatment or the placebo, ensuring unbiased results. The study will include a screening period to determine eligibility, a treatment period where the injections are given, and a follow-up period to monitor participants’ health and response to the treatment.

Participants will be divided into three groups, each receiving different doses of the RBD1016 Injection. The study will monitor the participants for any side effects and measure how well the treatment works in reducing the levels of the virus in the body. The trial aims to provide valuable information on the potential benefits and risks of using RBD1016 Injection for treating chronic hepatitis B, contributing to the development of new treatment options for this condition.

The study will begin with healthy volunteers to assess the initial safety of BJT-778. Following this, individuals with Chronic Hepatitis B and Chronic Hepatitis D will participate to further evaluate the treatment’s effects. Participants will receive injections and be monitored for any side effects or changes in their health. The study will also measure how the body processes the drug and its impact on the viruses causing the infections.

Throughout the study, researchers will collect data on the participants’ health and any changes in their condition. This information will help determine the potential benefits and risks of BJT-778 for treating these chronic liver infections. The study is expected to continue until early 2025, providing valuable insights into the treatment’s effectiveness and safety.

The study involves two groups of participants. The first group includes teenagers aged 12 to under 18 years, and the second group includes children aged 2 to under 12 years. Participants in both groups will receive either Tenofovir Alafenamide or a placebo once a day. The study will last for several weeks, during which the safety and effectiveness of the medication will be closely monitored. The goal is to see if the medication can reduce the amount of hepatitis B virus in the body and improve liver health.

Throughout the study, participants will have regular check-ups to monitor their health and any side effects they might experience. The study will also look at how the medication is processed in the body, which is known as pharmacokinetics. This information will help determine the best dose for treating Chronic Hepatitis B in children and teenagers. The study is expected to continue for several years to gather comprehensive data on the long-term effects of the treatment.

The purpose of the study is to evaluate how well these treatments work in managing chronic HBV infection. Participants will receive the treatments over a period of time, with regular monitoring to assess the effects. The study will involve injections and oral tablets, depending on the specific treatment being tested. Participants will be monitored for changes in their health and any side effects that may occur during the study.

The study aims to determine if the treatments can effectively reduce the levels of the virus in the body and improve the health of those with chronic HBV infection. The results will help in understanding the potential benefits and risks of these investigational therapies for managing the disease. Participants will be closely observed throughout the study to ensure their safety and to gather important data on the treatments’ effectiveness.